Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment

Rigault, Eugénie; Lacas, Benjamin; Gléhen, Olivier; Smith, Denis; Dupont-Bierre, Eric; Guimbaud, Rosine; Malka, David; Boige, Valérie; Fuerea, Alina; Pignon, Jean‐Pierre; Ducreux, Michel

doi:10.1016/j.ctarc.2022.100674

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship between VEGF and CRLM is de nite, and anti-VEGF drugs have been widely used in the treatment of CRC. For example, bevacizumab plus standard chemotherapy improves survival in patients with unresectable CRLM [32]. CXCL12 has also been found to be involved in CRLM.…”

Section: Discussionmentioning

confidence: 99%

The risk factors for colorectal cancer liver metastasis in a mouse model of Alzheimer's disease

Nie,

Qiao,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background and Objective: To investigate the occurrence of colorectal cancer (CRC) liver metastasis (CRLM) and the risk factors in mice with Alzheimer's disease (AD). methods: Mice in the AD group (APP/PS1 models of AD) and the control (CON) group (wild-type C57BL/6J mice) were injected with MC38 cells to establish CRLM models. After the experiment, the tumor nodules on liver surface were counted, and the liver weight, volume were measured. 16S rDNA sequencing, enzyme-linked immunosorbent assay, Pearson’s analysis and immunohistochemical technique were showed to investigate the impact of AD on CRLM and its possible mechanism. Results: Compared to the CON group, the AD group exhibited a increase in the number of tumor nodules on the liver surface, with consistent findings in both liver weight and volume measurements correlating with the metastatic count. Analysis of 16S rDNA sequencing revealed distinct alterations in the intestinal microbiota of the AD group. Furthermore, relative to the CON group, the AD group exhibited notably elevated levels of NGF expression in both the colon and liver. Additionally, discernibly elevated concentrations of VEGF and CXCL12 were observed in both serum and liver tissues of the AD group compared to the CON group. The results of Pearson correlation analysis indicated positive correlations between intestinal NGF levels and both hepatic CXCL12 and VEGF levels. The AD group had smaller number of hepatic KCs than that in the CON group. Conclusions: AD accelerates CRLM. The mechanism may be caused by gut flora affecting hepatic KCs, thus linking the brain-gut-liver axis.

show abstract

Section: Discussionmentioning

confidence: 99%

The risk factors for colorectal cancer liver metastasis in a mouse model of Alzheimer's disease

Nie,

Qiao,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…No deaths occurred due to drug toxicity. Although the study had to be halted due to poor funding and fewer patients, it did show that bevacizumab HAI can be safely used alongside systemic chemotherapy in patients with unresectable colorectal liver metastases [ 29 ].…”

Section: Reviewmentioning

confidence: 99%

“…Liver enzymes and bilirubin elevation [21,23,29] Grade 4 thrombocytopenia, grade 4 hypokalemia, nausea, vomiting, constipation, and diarrhea [17,29]; neutropenia (>= grade 3) [20,21,23,29]; Advanced uveal melanoma with hepatic metastases (HAI)…”

Section: Retinoblastomamentioning

confidence: 99%

The Evolving Role of Intra-arterial Chemotherapy in Adult and Pediatric Cancers: A Comprehensive Review

Tangella

2023

Cureus

View full text Add to dashboard Cite

The development of intra-arterial chemotherapy (IAC) was driven by an ambition to mitigate systemic side effects, enhance the bioavailability of drugs, and optimize the efficacy of chemotherapeutic agents. While the initial research on IAC primarily examined its effectiveness in treating various liver malignancies, the application of this treatment has undergone significant advancements since its introduction. The primary objective of this article is to examine the current range of utilization of IAC, both with and without radiotherapy, while also evaluating the results of relevant clinical trials. Furthermore, this article explores potential future advancements and opportunities in this field. From the scoping review of available articles, it can be concluded that IAC is an effective treatment alternative and, sometimes, a better first-line option, but there is a need for more evidence to make IAC a regular treatment option available for patients.

show abstract

Unleashing the potential: transarterial chemoembolization combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma

Xie,

Yang,

Hao

et al. 2024

Clin Transl Oncol

View full text Add to dashboard Cite

Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment

Cited by 4 publications

References 22 publications

The risk factors for colorectal cancer liver metastasis in a mouse model of Alzheimer's disease

The risk factors for colorectal cancer liver metastasis in a mouse model of Alzheimer's disease

The Evolving Role of Intra-arterial Chemotherapy in Adult and Pediatric Cancers: A Comprehensive Review

Unleashing the potential: transarterial chemoembolization combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma

Contact Info

Product

Resources

About